These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16521323)

  • 21. Concurrent radiation therapy and bortezomib in myeloma patient.
    Berges O; Decaudin D; Servois V; Kirova YM
    Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
    Rukavitsyn OA
    Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 24. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 25. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 26. Medullary renal cell carcinoma and response to therapy with bortezomib.
    Ronnen EA; Kondagunta GV; Motzer RJ
    J Clin Oncol; 2006 Mar; 24(9):e14. PubMed ID: 16549825
    [No Abstract]   [Full Text] [Related]  

  • 27. Review. Clinical pharmacokinetics of bortezomib.
    Levêque D; Carvalho MC; Maloisel F
    In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
    Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Lazzarino M; Corso A
    Leuk Res; 2008 May; 32(5):839-41. PubMed ID: 17997154
    [No Abstract]   [Full Text] [Related]  

  • 29. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
    Olivier S; Robe P; Bours V
    Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A; Gahres N
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 32. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.
    Orciuolo E; Galimberti S; Petrini M
    Leuk Res; 2007 Jul; 31(7):1026-7. PubMed ID: 17045335
    [No Abstract]   [Full Text] [Related]  

  • 34. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
    Boulanger E; Meignin V; Oksenhendler E
    Br J Haematol; 2008 May; 141(4):559-61. PubMed ID: 18341641
    [No Abstract]   [Full Text] [Related]  

  • 35. Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
    Garfield DH; Cadranel JL
    Lung Cancer; 2007 Aug; 57(2):249-50. PubMed ID: 17599646
    [No Abstract]   [Full Text] [Related]  

  • 36. US NHGRI launches chemical attack on drug development gap.
    Garber K
    Nat Biotechnol; 2003 Nov; 21(11):1253-4. PubMed ID: 14595338
    [No Abstract]   [Full Text] [Related]  

  • 37. Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
    Galimberti S; Canestaro M; Ciancia E; Fazzi R; Marasca R; Petrini M
    Leuk Res; 2008 Aug; 32(8):1324-5. PubMed ID: 18192008
    [No Abstract]   [Full Text] [Related]  

  • 38. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.